TD Cowen cut shares of Kronos Bio (NASDAQ:KRON - Free Report) from a buy rating to a hold rating in a report released on Thursday, Marketbeat Ratings reports.
A number of other equities analysts also recently weighed in on KRON. HC Wainwright reaffirmed a "buy" rating and set a $2.25 target price on shares of Kronos Bio in a research note on Monday, August 19th. Piper Sandler reissued an "overweight" rating and set a $6.00 price target on shares of Kronos Bio in a research report on Tuesday, October 8th.
Get Our Latest Report on KRON
Kronos Bio Stock Down 3.1 %
Shares of KRON stock traded down $0.03 during mid-day trading on Thursday, reaching $0.85. 478,167 shares of the company's stock traded hands, compared to its average volume of 266,102. The company's 50-day moving average price is $0.95 and its 200-day moving average price is $1.03. The company has a market cap of $51.40 million, a P/E ratio of -0.51 and a beta of 1.86. Kronos Bio has a 12 month low of $0.69 and a 12 month high of $1.60.
Institutional Investors Weigh In On Kronos Bio
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Kronos Bio by 14.6% during the first quarter. Vanguard Group Inc. now owns 1,948,595 shares of the company's stock valued at $2,533,000 after acquiring an additional 247,918 shares during the period. Acadian Asset Management LLC raised its stake in Kronos Bio by 17.2% during the 1st quarter. Acadian Asset Management LLC now owns 774,559 shares of the company's stock valued at $1,005,000 after purchasing an additional 113,618 shares during the period. Forefront Analytics LLC lifted its holdings in Kronos Bio by 75.0% in the 2nd quarter. Forefront Analytics LLC now owns 134,998 shares of the company's stock worth $167,000 after purchasing an additional 57,867 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Kronos Bio in the 1st quarter worth approximately $71,000. 64.09% of the stock is owned by hedge funds and other institutional investors.
About Kronos Bio
(
Get Free Report)
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Read More
Before you consider Kronos Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kronos Bio wasn't on the list.
While Kronos Bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
